Nuformix plc (LON:NFX – Get Free Report) shares fell 12.5% on Monday . The company traded as low as GBX 0.14 ($0.00) and last traded at GBX 0.14 ($0.00). 621,549 shares were traded during trading, a decline of 80% from the average session volume of 3,147,163 shares. The stock had previously closed at GBX 0.16 ($0.00).
Nuformix Stock Performance
The company has a current ratio of 1.12, a quick ratio of 3.35 and a debt-to-equity ratio of 1.17. The business’s 50 day moving average is GBX 0.17 and its two-hundred day moving average is GBX 0.19. The company has a market cap of £1.15 million, a PE ratio of -1.63 and a beta of 1.22.
About Nuformix
Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.
See Also
- Five stocks we like better than Nuformix
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Symbotic’s Double-Bagger Potential as It Hits a Key Inflection
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- High Dividend Yields Make These 2 Shipping Stocks Stand Out
- The How and Why of Investing in Gold Stocks
- Can Celsius Stock Rebound? Analysts See 74% Upside Potential
Receive News & Ratings for Nuformix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuformix and related companies with MarketBeat.com's FREE daily email newsletter.
